Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Jordan M. Winter; Charles J. Yeo; Jonathan R. Brody

doi:10.1002/jso.23192

Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Jordan M. Winter, Charles J. Yeo, Jonathan R. Brody

Research output: Contribution to journal › Article › peer-review

198 Scopus citations

Abstract

Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15-22.

Original language	English (US)
Pages (from-to)	15-22
Number of pages	8
Journal	Journal of surgical oncology
Volume	107
Issue number	1
DOIs	https://doi.org/10.1002/jso.23192
State	Published - Jan 2013
Externally published	Yes

Keywords

biomarkers
pancreatic cancer
pancreatic ductal adenocarcinoma
predictive markers
prognostic markers

ASJC Scopus subject areas

Surgery
Oncology

Access to Document

10.1002/jso.23192

Cite this

@article{5fd28304f8084ac685e1bfebe449f1fc,

title = "Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer",

abstract = "Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15-22.",

keywords = "biomarkers, pancreatic cancer, pancreatic ductal adenocarcinoma, predictive markers, prognostic markers",

author = "Winter, {Jordan M.} and Yeo, {Charles J.} and Brody, {Jonathan R.}",

year = "2013",

month = jan,

doi = "10.1002/jso.23192",

language = "English (US)",

volume = "107",

pages = "15--22",

journal = "Journal of surgical oncology",

issn = "0022-4790",

publisher = "Wiley-Liss Inc.",

number = "1",

}

TY - JOUR

T1 - Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

AU - Winter, Jordan M.

AU - Yeo, Charles J.

AU - Brody, Jonathan R.

PY - 2013/1

Y1 - 2013/1

N2 - Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15-22.

AB - Serum CA 19-9 is the only FDA approved biomarker recommended for use in the routine management of pancreatic ductal adenocarcinoma (PDA). Over 2,000 biomarker studies related to pancreatic cancer appear in the literature, highlighting the need to discover and develop improved tests. Diagnostic biomarkers have implications for early detection of PDA, prognostic markers predict patient survival and recurrence patterns, and predictive markers can help personalize treatment regimens. J. Surg. Oncol. 2013;107:15-22.

KW - biomarkers

KW - pancreatic cancer

KW - pancreatic ductal adenocarcinoma

KW - predictive markers

KW - prognostic markers

UR - http://www.scopus.com/inward/record.url?scp=84871298277&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871298277&partnerID=8YFLogxK

U2 - 10.1002/jso.23192

DO - 10.1002/jso.23192

M3 - Article

C2 - 22729569

AN - SCOPUS:84871298277

SN - 0022-4790

VL - 107

SP - 15

EP - 22

JO - Journal of surgical oncology

JF - Journal of surgical oncology

IS - 1

ER -

Diagnostic, prognostic, and predictive biomarkers in pancreatic cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this